Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial

• Status: Unknown status
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Liver disease is an important cause of death in type 2 diabetes. In the population-based Verona Diabetes Study cirrhosis was the fourth leading cause of death and accounted for 4.4% of diabetes-related deaths. In another prospective cohort study , cirrhosis accounted for 12.5% of deaths in patients with diabetes. In Egypt hepatitis C virus the commonest of cirrhosis here has a prevalence of 9.8% in the population with the greatest burden over national health care bills. Patients with cirrhosis & type 2 diabetes mellitus are always showing up in all hospital wards without a clear consensus of best management of their hyperglycemia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Collaborator: Sanofi
• Treatments: Insulin; Insulin Glargine; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Hospitalized type 2 Diabetes Mellitus with liver cirrhosis

• Entry blood glucose (fasting or random) greater than 180 mg%

Exclusion Criteria:

• Type 1 Diabetes Mellitus

• Pregnancy

• Steroids: prednisone greater than 7.5mg/day or equivalent

• Serum Creatinine > 3 mg/dl

• Patients in intensive care units.